LumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...

Moreover, the outlook for Syfovre is not promising ... Additionally, the anticipated market share gains by Izervay pose a significant challenge, and price discounts are not fully factored in as growth ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) are down by about 62% from the peak they reached in January. However, ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...